Skin cancer is among one of the most common human malignancies wide-spread world-over with mortality statistics rising continuously at an alarming rate. The increasing frequency of these malignancies has marked the need for adopting effective treatment plan coupled with better and site-specific delivery options for the desired therapeutic agent's availability at the affected site. The concurrent delivery approaches to cancerous tissues are under constant challenge and, as a result, are evolving and gaining advancements in terms of delivery modes, therapeutic agents and site-specificity of the therapeutics delivery. The lipid-based liposomal drug delivery is an attractive and emerging option, and which is meticulously shaping up beyond a threshold level to a promising, and viable route for the effective delivery of therapeutic agents and other required injuctions to the skin cancer. An update on liposomal delivery of chemotherapeutic agents, natural-origin compounds, photosensitizer, and DNA repair enzymes as well as other desirable and typical delivery modes employed in drug delivery and in the treatment of skin cancers is discussed in details. Moreover, liposomal delivery of nucleic acid-based therapeutics, i.e., small interfering RNA (siRNA), mRNA therapy, and RGD-linked liposomes are among the other promising novel technology under constant development. The current clinical applicability, viable clinical plans, future prospects including transport feasibility of delivery vesicles and imaging techniques in conjunction with the therapeutic agents is also discussed. The ongoing innovations in liposomal drug delivery technology for skin cancers hold promise for further development of the methodology for better, more effective and site-specific delivery as part of the better treatment plan by ensuring faster drug transport, better and full payload delivery with enough and required concentration of the dose.

皮肤癌是世界范围内最常见的人类恶性肿瘤之一，死亡率统计数字以惊人的速度持续上升。这些恶性肿瘤的发生频率增加，标志着需要采用有效的治疗计划，以及针对患病部位所需治疗剂的可用性提供更好的针对特定地点的治疗方案。癌组织的同时递送方法一直受到挑战，结果，在递送方式，治疗剂和治疗剂的位点特异性方面不断发展并取得进展。基于脂质的脂质体药物输送是一种有吸引力的新兴方法，它正在精心打造，超过阈值水平，成为一个有前途的，有效地向皮肤癌递送治疗剂和其他所需伤害的可行途径。详细讨论了化学治疗剂，天然来源的化合物，光敏剂和DNA修复酶的脂质体递送以及在药物递送和皮肤癌治疗中采用的其他理想且典型的递送方式的更新。而且，脂质体递送基于核酸的治疗剂我。例如，小干扰RNA（siRNA），mRNA治疗和RGD连接的脂质体是在不断发展中的其他有前途的新技术。还讨论了当前的临床适用性，可行的临床计划，包括输送囊泡的运输可行性和与治疗剂结合的成像技术在内的未来前景。用于皮肤癌的脂质体药物传递技术的不断创新为通过更好的治疗方案，确保更快的药物传递，更好的和充分的有效载荷传递以及足够和充分的传递，为更好，更有效和针对特定部位的传递方法的进一步发展提供了希望。所需的剂量浓度。